首页 正文

Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer

{{output}}
Background: Inavolisib is a highly potent and selective inhibitor of the alpha isoform of the p110 catalytic subunit of the phosphatidylinositol 3-kinase complex (encoded by PIK3CA) that also promotes the degradation of mutated p... ...